Home / Health / FDA Fast Track for Rare Heart Disease Drug
FDA Fast Track for Rare Heart Disease Drug
5 Mar
Summary
- Affinia's AFTX-201 targets BAG3-associated dilated cardiomyopathy.
- AFTX-201 is a one-time intravenous gene therapy for adults.
- The FDA granted fast track designation for potential accelerated approval.
Affinia Therapeutics announced its investigational gene therapy, AFTX-201, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). This designation is for the treatment of BAG3-associated dilated cardiomyopathy (DCM), a rare genetic heart condition.
AFTX-201 is being developed as a one-time intravenous gene therapy for adults diagnosed with BAG3 DCM. The therapy utilizes a novel capsid engineered for cardiac transduction, delivering a BAG3 transgene at significantly lower doses than existing gene therapies.
The treatment is currently under evaluation in the Phase I/II UPBEAT clinical trial. This multi-center, open-label study is assessing the pharmacodynamics, safety, tolerability, and preliminary efficacy of AFTX-201 in patients with BAG3 DCM.
The FDA's Fast Track Designation is intended to accelerate the development and review of drugs that treat serious conditions and address unmet medical needs. This designation will allow Affinia Therapeutics to benefit from early and frequent FDA feedback throughout the development process, potentially leading to a reduced time to market.
This designation follows a recent $40 million Series C funding round for Affinia Therapeutics in October 2025, indicating strong investor confidence in the company's pipeline and therapeutic approach.
